Divarasib for untreated lung cancer with KRAS G12C
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies divarasib to see if it is safe and can shrink or control advanced lung cancer. Participants must have a KRAS G12C mutation and have not had prior treatment for their advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic non-small cell lung cancer that can’t be cured with surgery or planned radiation and chemo
- Your tumor testing shows the KRAS G12C mutation, using required archived tumor samples
- You have not received prior whole-system (systemic) treatment for advanced/metastatic non-small cell lung cancer
- Your overall health is good enough (ECOG 0 or 1)
- Your cancer has measurable signs the study can track, and brain metastases (if included) must meet specific size/symptom rules
- You are not in the excluded groups (for example, squamous lung cancer, prior KRAS G12C inhibitor, or active untreated brain metastases in some groups)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (Calderasib and Pembrolizumab) in people with a specific type of advanced lung cancer (non-small cell lung cancer) that has a KRAS G12C mutation and high PD-L1 levels. It aims to see if this treatment can help shrink or control the cancer.
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
This study tests whether a drug called divarasib can help prevent lung cancer from coming back after surgery and initial treatment. You would only qualify if your cancer has a specific genetic mutation (KRAS G12C) and you've already had surgery and chemotherapy with immunotherapy.
This program provides access to an investigational drug called divarasib for people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C) and has progressed after previous treatment. The goal is to make this drug available to patients who may not have other options.
This Phase 2 trial studies sotorasib, a targeted medicine, in people with non-small cell lung cancer (NSCLC) that has a specific KRAS mutation called G12C. You may be eligible if your cancer has spread or can’t be removed by surgery and has grown again after at least one previous treatment.
This trial tests whether adding a new drug (zoldonrasib) to standard chemotherapy and immunotherapy can help people with a specific type of lung cancer. It is for those with a RAS G12D mutation and no prior treatment for metastatic disease.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.